Health In Tech initiated with a Buy at Maxim

Maxim initiated coverage of Health In Tech (HIT) with a Buy rating and $2.50 price target The company operates in a multi-billion-dollar market, with mostly recurring revenue and high gross margin, and the firm expects growth from new services and expansion into the mid-size employer market, the analyst tells investors in a research note. Maxim adds that its rating reflects its positive view of the large market opportunity, competitive advantages, and multiple growth initiatives.